Murthy P, Zenati MS, Al Abbas AI, et al. - Given the recent emergence of the SII, calculated using absolute platelet, neutrophil, and lymphocyte counts, as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed at diagnosis, researchers investigated its prognostic significance before and after neoadjuvant therapy (NAT) and its association with the pancreatic tumor biomarker carbohydrate-antigen 19-9 (CA 19-9). They performed a retrospective analysis of 419 PDAC patients treated with NAT before pancreatic resection at a single institution between 2007 and 2017. Findings revealed that pre-NAT SII has no significant correlation with clinical outcomes. When assessed as a continuous variable, elevated post-NAT SII was identified to be an independent, negative predictor of overall survival. They identified an independent predictive value of an 80% reduction in SII for a CA 19-9 response after NAT. Findings thereby suggest a possible value of posttreatment SII as a prognostic marker in PDAC patients receiving NAT.